Next™ BriefCAR-T for Autoimmune Disease and the New Immunology Frontier
Buy Now
Meticulous Next™HealthcareNov 2026106 ppMRN-1329

CAR-T for autoimmune disease Market Outlook 2026–2036: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

Brief ID: MRN-1329Format: PDF + Summary DeckDelivery: InstantHorizon: 10-yr horizonSignal: High-impact
Buy Now · $950
Adoption maturity (indexed)
Mainstream inflection: ~2032
Horizon: 2026–2036 · Signal: High-impact
10 yrs
Forward horizon
~2032
Mainstream inflection
High impact
Signal strength

What This Brief Covers

This Meticulous Next™ brief examines CAR-T cell therapy for autoimmune disease, in which engineered T cells remove the B cells that drive diseases such as lupus, myasthenia gravis and stiff person syndrome. It tests how fast early data turn into filings and approvals, and which participants capture value among developers, large biopharma firms, treatment centres, payers and manufacturing suppliers.

Kyverna Therapeutics initiated a rolling Biologics License Application for its CAR-T miv-cel (KYV-101) in stiff person syndrome with its first quarter 2026 results, and in August 2026 stated that it was on track to complete the submission in the fourth quarter of 2026. In October 2026 it presented the full one-year registrational data set showing sustained clinical benefit at MS Toronto, and in September 2026 it reported positive one-year durability data in stiff person syndrome and generalized myasthenia gravis. The conclusion is that the first CAR-T filing for an autoimmune disease is under way, and durability beyond one year is the evidence that regulators and payers will weigh.

The programme extends beyond neurology. The FDA granted RMAT designation for non-active secondary progressive multiple sclerosis in August 2026, updated data in treatment-refractory rheumatoid arthritis were presented at EULAR in June 2026, and a commercial manufacturing and supply agreement with ElevateBio was announced in July 2026. The conclusion is that one product is being prepared for several diseases and for commercial supply.

Lupus remains a main target. About 40% of lupus patients may develop nephritis and about 60% of those are expected to fail standard treatment, according to the developer,. Cabaletta Bio and Cullinan Therapeutics compete in lupus. The conclusion is that the lupus opportunity is large and the evidence is still earlier than in stiff person syndrome.

The brief treats CAR-T for autoimmune disease as a high-impact category with a ten year horizon to 2036 and identifies which diseases scale first and what each means for developers, large biopharma firms and payers.

It is a focused 106-page decision brief for biopharma firms, payers and investors. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which diseases scale first and who captures value.

Brief Snapshot
ParameterDetails
Forward horizon2026–2036 (10 years)
Emerging forceCAR-T for autoimmune disease: lupus and myasthenia gravis data spurring pivotal programmes
Technology readinessFirst rolling BLA in stiff person syndrome expected to complete in the fourth quarter of 2026; myasthenia gravis, lupus and multiple sclerosis programmes in clinical trials; commercial supply agreement signed
Indicative market size & forecastThe CAR-T for autoimmune disease market, covering CAR-T and related cell therapies for autoimmune disease in development and early use, related licensing and collaboration revenue, and related manufacturing and services, is valued at USD 0.1–0.2 billion in 2026 and is projected to reach USD 2.89–5.79 billion by 2036, at a CAGR of 40%
Mainstream inflection~2032, when approvals in several autoimmune diseases and lower cost manufacturing support routine use in refractory patients
Signal strengthA rolling BLA, one-year registrational data and an RMAT designation within about six months
Primary beneficiariesDevelopers with registrational data; large biopharma firms with partnered programmes; suppliers with scaled cell manufacturing
Brief length / format106 pages · PDF + executive summary deck · instant delivery

Understanding the Technology

T cells collected from the patient are engineered to carry a chimeric antigen receptor that targets CD19 on B cells, expanded and infused after lymphodepletion.

The treatment removes the B cells that produce harmful antibodies, and the immune system rebuilds with new B cells, which gives the prospect of remission without continuing drugs.

Safety centres on cytokine release, neurotoxicity and infection risk, managed in specialist centres.

Uses are neurology, rheumatology and nephrology, including stiff person syndrome, myasthenia gravis, lupus, multiple sclerosis and rheumatoid arthritis.

The limits are cost and complexity of treatment, the durability of remission, competition from antibodies and T cell engagers and funding of developers. The decade turns on whether one infusion gives remission that lasts for years.

Market Outlook

The CAR-T for autoimmune disease market, covering CAR-T and related cell therapies for autoimmune disease in development and early use, related licensing and collaboration revenue, and related manufacturing and services, is valued at USD 0.1–0.2 billion in 2026 and is projected to reach USD 2.89–5.79 billion by 2036, at a CAGR of 40%.

The 2026 base rests on collaboration and licensing revenue, trial related manufacturing and a first commercial supply agreement. Growth then follows the first approvals, wider filings in myasthenia gravis, lupus and multiple sclerosis and falling cost per patient.

The forecast is sensitive to durability data, the FDA decision on the first filing and payer coverage.

Scenarios

The base case assumes the first approval arrives around 2027 and registrational data in lupus and myasthenia gravis support approvals by 2030, giving the inflection in 2032. An accelerated case assumes fast approvals and lower manufacturing cost, bringing the inflection to 2030 and lifting the 2036 value to the top of the range. A delayed case assumes durability concerns and slow payer coverage, holding growth at the bottom of the range.

Factors Behind Growth

Growth drivers

  • Refractory disease with limited options.
  • Chronic cost of lifelong immunosuppressive treatment.
  • Early clinical data on remission and safety.
  • Reuse of the platform across many diseases.

Enablers

  • Large biopharma collaborations.
  • Developer and manufacturer partnerships.
  • Public research funding.
  • Commercial manufacturing and supply agreements.

Restraints and barriers

  • Cost and complexity of treatment.
  • Competition from antibodies and T cell engagers.
  • Safety, infection risk and lymphodepletion needs.
  • Funding constraints at developers.

The Forces at Play

The direction of CAR-T for autoimmune disease is set by demand from neurology and rheumatology patients, regulation, new targets and in vivo methods, treatment centre and payer adoption, and manufacturing cost.

Adoption Outlook

How the shift is likely to unfold across three time horizons.

Near term2026–2029
First filings

First approval decision and further registrational read-outs in neurology.

Mid term2029–2032
Wider approvals

Approvals broaden to rheumatology and nephrology.

Long term2032–2036
Wider uses

CAR-T for autoimmune disease moves to earlier lines and more diseases.

Latest Strategic Developments

DateDevelopmentTypeSignificance
May 2026Kyverna Therapeutics initiates a rolling BLA submission for miv-cel in stiff person syndromeRegulationFirst rolling BLA for a CAR-T in autoimmune disease
Jun 2026Updated miv-cel data in ACPA-positive, treatment-refractory rheumatoid arthritis are presented at EULARClinicalExtends the programme to rheumatology
Jul 2026Kyverna Therapeutics signs a commercial manufacturing and supply agreement with ElevateBio for miv-celManufacturingPrepares commercial supply
Aug 2026Kyverna Therapeutics announces RMAT designation for non-active secondary progressive multiple sclerosis and states it is on track to complete the SPS filing in the fourth quarterRegulationAdds expedited development in a third disease group
Sep 2026Kyverna Therapeutics reports positive one-year durability data for miv-cel in stiff person syndrome and generalized myasthenia gravisClinicalSupports durability beyond one year
Oct 2026Kyverna Therapeutics presents the full one-year registrational data set in stiff person syndrome at MS TorontoClinicalCompletes the data package for the first filing

Key Players & Competitive Landscape

The key participants in CAR-T for autoimmune disease include Kyverna Therapeutics, Inc., Cabaletta Bio, Inc., Cullinan Therapeutics, Inc., Autolus Therapeutics plc, Cartesian Therapeutics, Inc., Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences, Inc., AstraZeneca PLC, AbbVie Inc., Eli Lilly and Company, Johnson & Johnson, ElevateBio, LLC, the treatment centres, patient groups, payers and societies, and the regulators and standards bodies listed by archetype below.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as CAR-T for autoimmune disease matures.

CAR-T developers such as Kyverna Therapeutics, Cabaletta Bio and Cullinan Therapeutics lead the clinical programmes, while large biopharma and cell therapy firms, cell manufacturing and tools suppliers, treatment centres, patient groups, payers and societies, regulators, and standards bodies shape how fast CAR-T reaches patients. Competitive intensity is moderate in 2026 because a few developers are in registrational trials and large firms are building positions, and it rises as approvals arrive and as off-the-shelf, in vivo and antibody competitors reach the same patients.

ArchetypeRepresentative playersPosition in 2026Outlook to 2036
CAR-T developersKyverna Therapeutics, Cabaletta Bio, Cullinan Therapeutics, Autolus Therapeutics, Cartesian Therapeutics, Allogene Therapeutics, Fate Therapeutics, CRISPR TherapeuticsCAR-T and related products for autoimmune diseaseDevelop and supply cell therapies
Large biopharma and cell therapy firmsBristol-Myers Squibb, Novartis, Gilead Sciences, AstraZeneca, AbbVie, Eli Lilly, Johnson & Johnson, Roche, TakedaAutologous, partnered and in vivo programmesLicense, acquire and commercialize cell therapies
Cell manufacturing and tools suppliersElevateBio, Lonza, Miltenyi Biotec, Thermo Fisher Scientific, Danaher, Charles River LaboratoriesCell processing, media and contract manufacturingMake and test cell products at scale
Treatment centres, patient groups, payers and societiesMayo Clinic, Friedrich-Alexander University Erlangen-Nuremberg, National Institutes of Health, Myasthenia Gravis Foundation of America, Lupus Foundation of America, American College of Rheumatology, European Alliance of Associations for Rheumatology, American Academy of Neurology, American Society of Gene & Cell Therapy, Alliance for Regenerative Medicine, UnitedHealth Group, CVS Health, Elevance HealthTreatment, guidance and coverageTreat patients, set practice and pay for care
Government agencies and regulatorsU.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Pharmaceuticals and Medical Devices Agency, National Medical Products Administration, Centers for Medicare and Medicaid ServicesApproval and coverageApprove products and set coverage
Standards bodiesFoundation for the Accreditation of Cellular Therapy, International Council for Harmonisation, United States PharmacopeiaAccreditation and quality standardsSet quality standards

Where value migrates.

In 2026 value sits with developers in registrational trials, with large firms that partner or acquire, and with suppliers of cell manufacturing. By 2032 it moves toward companies with approved products in several autoimmune diseases, because payers cover treatments that give remission without continuing drugs. By 2036 it settles in integrated cell therapy and manufacturing platforms. Margins hold for products with durable remission and narrow for late followers.

Who Will Win — and Why

The archetypes best positioned to capture value as the shift matures.

Developers with registrational data

Firms that show durable remission and safety in filed indications.

Large biopharma firms with partnered programmes

Firms that bring registrational capacity and commercial reach.

Suppliers with scaled cell manufacturing

Firms that cut cost per patient as volume grows.

Regulatory Landscape

JurisdictionMilestoneIndicative timingEffect on adoption
FDA guidance for cell and gene therapy productsUS guidance on development and manufacture of cell therapiesIn forceShapes trial design and quality expectations
EU rules for advanced therapy medicinal productsEU framework for approval of advanced therapiesIn forceSets the approval path in Europe
Clinical trial approvals in the United States and EuropeRegulatory clearance for first-in-human and early trialsIn forceAllows early programmes to enter patients
Long term follow-up requirementsRequirements to follow treated patients for yearsIn forceAdd cost and time to development
Regenerative medicine advanced therapy designationUS programme that speeds development of serious condition cell therapiesIn forceGranted to a CAR-T for multiple sclerosis in August 2026

Investment Signals

The signals converge on the first filing for the field. A CAR-T for stiff person syndrome is completing a rolling BLA, one-year registrational and durability data were reported in September and October 2026, and an RMAT designation and a commercial supply agreement followed within about three months. Each signal supports growth, and approval and payer coverage are still to come.

Structural limits include cost and complexity of treatment, safety and infection risk, competition from antibodies and T cell engagers and funding constraints. The brief tracks the FDA decision on the first filing, registrational read-outs in myasthenia gravis and lupus, payer coverage and cost per patient.

Stiff person syndrome and myasthenia gravis, then lupus and multiple sclerosis, then other diseases are the expected order of development.

Questions This Brief Answers

01What is CAR-T for autoimmune disease, and why does it matter?
02What is the market size in 2026, and what is the forecast to 2036?
03What do the first filing and the durability data indicate?
04What factors are driving growth, and what cost and competition barriers remain?
05Which key participants are active, and which archetypes are positioned to win?
06What are the latest developments?
07How will approvals shape adoption between 2026 and 2036?
08What should developers, biopharma firms and payers do now?

Strategic Implications

  • CAR-T developers: complete registrational trials and show durable remission beyond one year.
  • Large biopharma firms: partner for registrational capacity and decide the balance between autologous, off-the-shelf and in vivo products.
  • Payers, treatment centres and suppliers: prepare coverage models and treatment pathways and scale cell processing and testing.
  • Policy makers: clarify evidence and follow-up requirements for CAR-T in non-cancer disease.
  • Investors: treat the first FDA decision, registrational read-outs, payer coverage and cost per patient as the leading indicators.
Analyst Perspective

"A single infusion that gives drug-free remission changes the economics of chronic disease. The first filing will show how regulators and payers value it."

Lead Foresight Analyst
Biotechnology & Life Sciences · Meticulous Next™

Table of Contents

Access & Licensing

A focused foresight brief, priced to circulate. Every option is delivered instantly and backed by analyst support.

Single Brief
$950
One named user
Full PDF brief
Executive summary deck
One named user
Free outlook update
★ Most Popular
Team License
$1,350
Up to 10 users
Access for 2–10 users
Internal sharing rights
30-minute analyst briefing
Enterprise
$2,150
Organization-wide
Organization-wide access
Unlimited users
Priority analyst access
Custom extracts
Included with
every brief
Analyst-reviewed foresightMulti-signal validationInstant deliveryFree outlook updates

Frequently Asked Questions

Search Market Intelligence

Search across reports, blogs, press releases, and industries